# BrainChild Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brainchild-bio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.brainchildbio.com
- Latest round: Series A (Sep 8, 2026)
- Investors on record: 2

## About

Based in the US, BrainChild Bio, Inc. offers a CAR-T platform designed for brain tumors to improve treatment outcomes for pediatric and adult central nervous system cancer patients. BrainChild Bio was established in 2023, founded by Michael Jensen, BrainChild Bio, Inc. the company focuses on developing innovative treatments for brain tumors, including diffuse intrinsic pontine glioma (DIPG), and has advanced its platform through venture funding and clinical development programs. In September 2026, BrainChild Bio, Inc. raised USD 116 million in series A funding co-led by unspecified investors, with participation from investor Seattle Children's Hospital Endowment and WRF Capital also participated in the round. Steven Brugger is serving the role of CEO. BrainChild Bio develops cellular immunotherapies targeting central nervous system cancers. Its platform incorporates multiplexed targeting of tumor antigens, potency-enhancing technologies, and remote-control capabilities for CAR-T therapies. The company's initial clinical programs focus on pediatric brain tumors, with plans to expand into additional pediatric and adult CNS malignancies. BrainChild Bio is a clinical-stage biotechnology company. Revenue generation is expected to come primarily from future commercialization of approved cell therapies, strategic partnerships, licensing agreements, research collaborations, and potential milestone payments. Public sources reviewed do not disclose any current commercial revenue figures. The company will use the September 2026 funding to advance its Phase 2 trial of BCB-276 for pediatric brain cancer and continue developing additional CAR-T therapies for brain tumors.

## Funding rounds

- Series A, Sep 8, 2026 — WRF Capital, Seattle Children's Hospital Endowment

## Investors

- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A
- Seattle Children's Hospital Endowment — Series A